Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05521542
Other study ID # CPDNV-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 30, 2023
Est. completion date April 2025

Study information

Verified date February 2023
Source Advanced NanoTherapies
Contact Marwan Berrada-Sounni
Phone (415) 517-0867
Email mberrada@advnanot.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective, single-arm, multi-center, safety and feasibility first-in-human study will evaluate the safety and feasibility of the SirPlux™ Duo Dual-API Coated PTCA Balloon Catheter to treat de-novo lesions between ≥2.25 and ≤4.0 mm in patients with stable symptomatic coronary artery disease.


Description:

The SirPlux Duo™ Dual API-Coated PTCA Balloon Catheter is an investigational medical device to be used to treat de-novo lesions in patients with symptomatic coronary artery disease. In this study, SirPlux Duo™ will be used in subjects undergoing a planned percutaneous coronary intervention. Population to treat will include those with de-novo coronary lesions in vessels with a reference vessel diameter (RVD) of ≥2.25 and ≤4.0 mm and a total lesion length of <35mm with documented symptomatic stable coronary artery disease. The study is a prospective, single-arm, multi-center, safety and feasibility first-in-human study designed to generate descriptive data about the use of SirPlux Duo™. The study primary performance endpoint is device success, technical success and procedural success. The safety primary endpoint (angiographic endpoint) is In-segment Late Lumen Loss (LLL) at 6 months. Other safety secondary clinical and angiographic endpoints (detailed below) will me measured during procedure up to 24 hours after discharge, at 30 days, 6 months, 12 months and 24 months after procedure.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date April 2025
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: 1. The subject is =18 years and <90 years old. 2. Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed. 3. Life expectancy > 1 year. 4. The subject is intended to undergo an angiographic procedure and coronary percutaneous intervention. The subject is an acceptable candidate for treatment in the Investigator's opinion and/or per hospital guidelines. 5. The subject is intended to undergo treatment with a coronary drug-coated balloon. 6. Women of child-bearing potential must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure. Men with a female partner of childbearing potential must agree to use condoms plus an additional reliable contraceptive method within 12 months after the index procedure. 7. The subject is able and willing to comply with all assessments in the study, including dual antiplatelet therapy (DAPT), ASA indefinitely, and P2Y12 inhibitor for a minimum of 6 months. 8. The subject shall be under optimal medical therapy for ASCVD, which includes at a minimum high-intensity statin therapy (atorvastatin 40-80 mg/d or rosuvastatin 20-40 mg/d). If statin intolerant, the patient should be treated with a PCSK9 inhibitor, ezetimibe or bempedoic acid. 9. Subject has chronic stable angina or has had an acute coronary syndrome and the cardiac biomarkers have returned to normal 10. Target lesion is located within a de-novo coronary artery located in a native coronary artery with a reference vessel diameter between =2.25 mm to =4.0mm by visual estimate, with a lesion length of equal greater 15mm to < 35mm. 11. Subject has multiple lesions that meet inclusion and exclusion criteria individually that could be treated with a study device. To be treated with a study device, lesions must be defined as target lesions. A maximum of three (3) lesions could be treated during the index procedure (maximum of 2 target vessels). One (1) non-target lesion can be staged if needed. Target lesions (up tp 2) cannot be staged. One investigational device is to be used per target lesion. 12. Successful pre-dilation with semi and/or non-compliant balloon of the target lesion(s) is defined as no major flow-limiting dissections (Grade C or higher) and =30% residual stenosis of the target lesion by a visual estimate on angiography. Adjunctive therapy pre-dilation therapies such as scoring balloon, cutting balloon, and IVL are allowed. Rotablator or similar rotational atherectomy devices are restricted per protocol. Exclusion Criteria: General Exclusion Criteria: 1. Subject has other serious medical illnesses (e.g., cancer, congestive heart failure) that may reduce life expectancy to less than 12 months. 2. Subject has current problems with substance abuse. 3. Subject has a planned procedure that may cause non-compliance with the protocol or confound data interpretation. 4. Subject participates in another investigational drug or device clinical study that has not reached its primary endpoint. 5. Subject intends to participate in another investigational drug or device clinical study within 12 months after the index procedure. 6. Significant target vessel tortuosity or other parameters that could prohibit access to the target lesion. 7. Type A lesions, Chronic total occlusion (CTO) of the target lesion(s) or Thrombolysis In Myocardial Infarction (TIMI) flow < 2. 8. Cardiogenic shock. 9. Subject requires treatment of a coronary lesion(s) involving a bifurcation. 10. Target lesion(s) within native or synthetic vessel grafts. 11. CTO of inflow vessel. 12. Subject has had any major (e.g., cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days before the index procedure or has a planned major surgical procedure or intervention within 30 days of the index procedure. 13. Subject requires treatment of a coronary lesion distal to the target lesion(s) at the time of the enrollment/index procedure. 14. The subject has a known coagulopathy or has a bleeding diathesis, thrombocytopenia (with platelet counts less than 100,000/microliter) or platelets > 400,000/microliter, or international normalized ratio >1.5. Patients on chronic oral anticoagulation medications will be excluded of the study 15. Known renal insufficiency (e.g., serum creatinine >2.5mg/dL, or creatinine clearance (CrCl) =30 mL/min). 16. Subject on dialysis, or acute kidney failure (as per physician judgment). 17. Subject in whom antiplatelet, anticoagulant or thrombolytic therapy is contraindicated or hypersensitive. 18. Subject has a known allergy to contrast agents or medications used to perform a coronary intervention that cannot be adequately pre-treated, including, but not limited to, sirolimus, paclitaxel, aspirin, heparin, clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor. 19. Subject has a known allergy to urethane, nylon, or silicone. 20. Myocardial infarction within 60 days before enrollment. 21. History of stroke/TIA within 60 days before enrollment. LVEF <30%. 22. Subject is confined to bed. 23. Subject has a life expectancy less than 12 months. 24. History of thrombolytic therapy within two weeks of enrollment. 25. Patient is a recipient of a heart transplant. 26. Patient is unwilling/not able to return for angiographic catheterization at 6-month follow-up. 27. Women who are pregnant, breast-feeding or intend to become pregnant. 28. Subject is planning to participate in other clinical studies before completing this study. 29. Subject has other medical, social, or psychological problems and is unwilling or unable to comply with procedures specified in the protocol, or may have difficulty returning for follow-up visits as specified by the protocol. 30. Cardiogenic shock (SBP <80mmHg requiring inotropes, IABP, or fluid support). 31. Known allergies to sirolimus, paclitaxel or other components of the used medical devices. 32. Subject with renal insufficiency (creatinine =2.0mg/dl) or failure (dialysis-dependent). 33. Subject has suspected or proven COVID-19 positive result at present or within the past 4 weeks of informed consent form. Angiographic Exclusion Criteria: 1. Subject has a planned intervention in the left-main plus two separate major epicardial territories (left-main plus 2 vessel diseases). 2. Target vessel size <2.0 mm or >4.0 mm 3. Target lesion in the left main stem and proximal LAD. 4. The target vessel contains visible thrombus. 5. Aorto-ostial target lesion (within 3 mm of the aorta junction); including all left main disease. 6. Moderate-severe tortuous, calcified, or angulated coronary anatomy of the target vessel that, in the opinion of the Investigator, would result in suboptimal imaging or excessive risk of complication from placement of an IVUS catheter following Clinical Decision. 7. The lesion is located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft. 8. Target lesions are located within a bifurcation of the planned treatment of side-branch vessel. 9. Target lesion is located within a previous implanted stent.

Study Design


Intervention

Device:
SirPlux™ Duo Dual-API Coated PTCA Balloon Catheter
SirPlux™ Duo Dual-API Coated PTCA Balloon Catheter is a Drug-Coated Balloon to treat de novo lesions in patients with symptomatic stable coronary artery disease

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide South Australia
Australia The Prince Charles Hospital Chermside Queensland
Australia Victorian Heart Institute - Monash University Clayton Victoria

Sponsors (4)

Lead Sponsor Collaborator
Advanced NanoTherapies Cardiovascular Research Foundation, New York, Cogent Technologies Corporation, Monash University

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance Endpoint 1 - Device Success: Defined as successful delivery, balloon inflation, deflation, and retrieval of the intact study device without burst below rated burst pressure (Peri-procedural)
Primary Performance Endpoint 2 - Technical Success: Defined as successful lesion crossing, completion of POBA and immediate achievement of <30% residual stenosis (by QCA) of the target lesion upon completion of angiography post investigational device inflation (Peri-procedural)
Primary Performance Endpoint 3 - Procedural Success: Defined as device success or technical success and absence of procedural complications following SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter inflation (ie absence of vessel dissection or loss of TIMI 3 flow) (Peri-procedural)
Primary Angiographic Endpoint (by QCA): In-segment Late Lumen Loss (LLL) at 6 months after the procedure
Secondary Safety Endpoint All-cause death
Target Vessel Myocardial Infarction (TVMI).
Cardiac death
Myocardial Infarction (MI)
Emergent Coronary Artery Bypass Graft (CABG)
Repeat Target Lesion Revascularization (TLR) (clinically driven) by percutaneous or surgical methods
Major Adverse Cardiac Event (MACE)
Target Vessel Failure (TVF)
Target Lesion Failure (TLF)
All revascularizations (TLR, TVR and non-TVR)
During procedure up to 24 hours, at 30 days, 6 months, 12 months and 24 months
Secondary Angiographic and IVUS Endpoint In-segment ( and in balloon) percent diameter stenosis (% diameter stenosis; DS). at 6 months post-procedure
Secondary Angiographic and IVUS Endpoint in-segment binary angiographic restenosis (BAR) rate [defined as =50% DS]. at 6 months post-procedure
Secondary Angiographic and IVUS Endpoint • In-segment (and in balloon) Minimum Luminal/Lumen Diameter (MLD) at 6 months post-procedure
Secondary Angiographic and IVUS Endpoint • In-segment (and in balloon) Change in IVUS MLA (mm2) at 6 months post-procedure
Secondary Angiographic and IVUS Endpoint • In-segment (and in balloon) Change in mean lumen area (mm2) at 6 months post-procedure
Secondary Angiographic and IVUS Endpoint • In-segment (and in balloon) Change in percentage atheroma volume at 6 months post-procedure
Secondary Angiographic and IVUS Endpoint • In-segment (and in balloon) Serial IVUS remodeling (change in vessel area/volume) at 6 months post-procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A